



Carvykti in Saudi Arabia

The SFDA named-patient coordination pathway – indicative 2026

ONCOLOGY · BCMA CAR-T MYELOMA

The clinical situation

Carvykti (ciltacabtagene autoleucel) is a one-time autologous BCMA-directed CAR-T infusion for relapsed/refractory multiple myeloma after prior PI, IMiD, and anti-CD38 exposure. Manufactured by Janssen with Legend Biotech. The journey involves apheresis, a multi-week manufacturing window, bridging therapy, lymphodepletion, infusion, and extended monitoring for CRS, ICANS, and cytopenia recovery. Administration must occur at a Carvykti-qualified CAR-T treatment centre.

The pathway, 5 steps

- 1 Consultation & eligibility.** Your haematologist reviews prior-line sequence, organ-system baseline, and fitness for lymphodepletion.
- 2 Treatment-centre referral.** Reserve Meds coordinates referral to a Carvykti-qualified centre (domestic or international) through our care-coordination network.
- 3 SFDA / MoH referral documentation.** Cross-border named-patient file: medical necessity, centre identification, return-to-home plan.
- 4 Apheresis & manufacturing window.** T-cell collection, shipment, bridging therapy during the multi-week manufacturing interval.
- 5 Lymphodepletion, infusion, monitoring.** Delivered at the qualified centre with intensive CRS/ICANS monitoring; long-term follow-up handed back to your Saudi haematologist.

Indicative economics

Reference US list range: USD 500,000–600,000 for the cell product; total cost of care with inpatient stay, apheresis, lymphodepletion, infusion, and monitoring typically USD 1.0M–1.5M (drug-only reference for the product; Reserve Meds provides a transparent delivered quote at intake).

Indicative first-dose timing

10–16 weeks from intake to infusion, driven by manufacturing window and treatment-centre calendar. Inpatient stay around lymphodepletion/monitoring typically 3–6 weeks. Indicative — not guaranteed.

Reserve Meds's role

Treatment-centre referral. Coordination with authorised Carvykti centres through our clinical network. **Documentation.** Cross-border referral and SFDA/MoH named-patient package. **Logistics.** Patient and caregiver travel, accommodation, return-home planning. **Concierge case lead.** Named point of contact throughout the extended treatment journey. **We are a**

coordinator — not the prescriber, not the manufacturer, not the treatment centre. All clinical decisions remain with your treating haematologist and the cell-therapy centre.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Carvykti × Saudi Arabia first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/carvykti-saudi-arabia.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team